Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
$0.00
$0.00
$0.08
$5K11.599,131 shsN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$3.15
-7.6%
$4.77
$1.04
$7.25
$47.13M-0.39870,485 shs120,657 shs
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
$3.65
+2.2%
$3.96
$2.83
$6.82
$161.24M1.1799,685 shs153,019 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.29
$0.37
$0.22
$4.79
$12.07M-0.281.09 million shs292,332 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$1.20
-4.8%
$1.78
$1.20
$14.83
$3.92M1.87962,295 shs291,008 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00%0.00%0.00%0.00%-99.85%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%+21.15%-43.04%-25.53%+105.88%
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
0.00%-4.95%-13.10%+4.29%+24.15%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
0.00%+10.09%-28.87%+8.43%-84.26%
Soligenix Inc. stock logo
SNGX
Soligenix
0.00%-11.76%-36.84%-34.78%-46.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.5831 of 5 stars
0.03.00.00.02.11.70.0
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
0.9035 of 5 stars
3.51.00.00.00.00.00.0
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
1.4352 of 5 stars
3.02.00.00.00.60.01.3
Soligenix Inc. stock logo
SNGX
Soligenix
1.5126 of 5 stars
0.05.00.00.02.60.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00
N/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00
N/AN/AN/A
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
3.00
Buy$8.00119.18% Upside
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.00
Hold$3.381,071.88% Upside
Soligenix Inc. stock logo
SNGX
Soligenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest DMAC, ARDS, CPIX, LPTX, and SNGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$37.87M1.24$0.26 per share12.25$1.61 per share1.96
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/A$0.95 per shareN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
Soligenix Inc. stock logo
SNGX
Soligenix
$120K32.60N/AN/A$1.64 per share0.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
-$30.37MN/A0.00N/AN/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$6.48M-$0.25N/AN/A-7.98%6.92%2.33%8/5/2025 (Estimated)
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)
Soligenix Inc. stock logo
SNGX
Soligenix
-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)

Latest DMAC, ARDS, CPIX, LPTX, and SNGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
-$0.18-$0.18N/A-$0.18N/AN/A
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
5/9/2025Q1 2025
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.67-$1.06-$0.39-$1.06N/AN/A
5/6/2025Q1 2025
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A$0.15N/A$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.18
1.25
1.09
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/A
8.02
8.02
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
2.41
2.41
Soligenix Inc. stock logo
SNGX
Soligenix
N/A
1.85
1.85
CompanyEmployeesShares OutstandingFree FloatOptionable
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
3053.32 million50.39 millionNot Optionable
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.96 million8.25 millionOptionable
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
2042.88 million39.75 millionOptionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable
Soligenix Inc. stock logo
SNGX
Soligenix
203.26 million3.16 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aridis Pharmaceuticals stock logo

Aridis Pharmaceuticals NASDAQ:ARDS

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.15 -0.26 (-7.62%)
As of 07/3/2025 03:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

DiaMedica Therapeutics stock logo

DiaMedica Therapeutics NASDAQ:DMAC

$3.65 +0.08 (+2.24%)
Closing price 07/3/2025 03:41 PM Eastern
Extended Trading
$3.72 +0.07 (+2.03%)
As of 07/3/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.29 0.00 (0.00%)
Closing price 07/3/2025 03:13 PM Eastern
Extended Trading
$0.29 0.00 (0.00%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$1.20 -0.06 (-4.76%)
Closing price 07/3/2025 03:50 PM Eastern
Extended Trading
$1.20 +0.01 (+0.42%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.